BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Despotes KA, Donaldson SH. Current state of CFTR modulators for treatment of Cystic Fibrosis. Current Opinion in Pharmacology 2022;65:102239. [DOI: 10.1016/j.coph.2022.102239] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Graciosa MD, Schivinski CIS, Manoel EJ, Ries LGK. Jaw and neck muscle activity during chewing and craniocervical dysfunction index in children, adolescents, and adults with and without cystic fibrosis: a comparative analysis. Cranio 2022;:1-10. [PMID: 36178327 DOI: 10.1080/08869634.2022.2128587] [Reference Citation Analysis]
2 Ribeiro CMP, Gentzsch M. Editorial overview - 2022 respiratory issue: Cystic fibrosis pathophysiology, models, and novel therapies. Curr Opin Pharmacol 2022;67:102289. [PMID: 36152600 DOI: 10.1016/j.coph.2022.102289] [Reference Citation Analysis]
3 Shimosegawa T. Between early and established chronic pancreatitis: A proposal of "acinar-ductal hybrid mechanism". Pancreatology 2022:S1424-3903(22)00743-8. [PMID: 36163223 DOI: 10.1016/j.pan.2022.09.239] [Reference Citation Analysis]
4 de Poel E, Spelier S, Hagemeijer M, van Mourik P, Suen S, Vonk A, Brunsveld J, Ithakisiou GN, Kruisselbrink E, Oppelaar H, Berkers G, de Winter-de Groot K, Heida-michel S, Jans S, van Panhuis H, Bakker M, van der Meer R, Roukema J, Dompeling E, Weersink E, Koppelman G, Blaazer A, Muijlwijk-koezen J, van der Ent C, Beekman J. FDA-Approved Drug Screening in Patient-Derived Organoids Demonstrates Potential of Drug Repurposing for Rare Cystic Fibrosis Genotypes.. [DOI: 10.1101/2022.09.02.506304] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 D’amore C, Borgo C, Bosello Travain V, Salvi M. KDM2A and KDM3B as Potential Targets for the Rescue of F508del-CFTR. IJMS 2022;23:9612. [DOI: 10.3390/ijms23179612] [Reference Citation Analysis]